A-1331852


CAS No. : 1430844-80-6

1430844-80-6
Price and Availability of CAS No. : 1430844-80-6
Size Price Stock
5mg $144 In-stock
10mg $228 In-stock
25mg $468 In-stock
50mg $744 In-stock
100mg $1320 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-19741
M.Wt: 658.81
Formula: C38H38N6O3S
Purity: >98 %
Solubility: DMSO : ≥ 50 mg/mL (75.89 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble); Ethanol : 4 mg/mL (6.07 mM; ultrasonic and warming and heat to 60°C)
Introduction of 1430844-80-6 :

A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM. IC50 & Target: Ki: less than 10 pM (BCL-XL)[1] In Vitro: A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC50s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC50 values of 3, 7, 80, 120 and 100 nM[1]. In Vivo: A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer[1].

Your information is safe with us.